Mar 24, 2016 12:24pm EDT OPKO To Present 18-24 Month Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) from Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study in Oral Presentation at ENDO 2016
Mar 16, 2016 8:30am EDT OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a Long-Acting Oxyntomodulin for the Treatment of Obesity and Type II Diabetes
Mar 15, 2016 2:05pm EDT OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines
Mar 15, 2016 8:30am EDT OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories
Mar 02, 2016 8:30am EST OPKO’s GeneDx Presenting on a Number of Topics at the 2016 ACMG Annual Clinical Genetics Meeting
Feb 24, 2016 8:30am EST OPKO's GeneDx Participating in the Molecular Medicine Tri-Conference 2016 in San Francisco
Feb 23, 2016 8:30am EST OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia
Feb 23, 2016 8:00am EST OPKO to Announce 2015 Fourth Quarter and Full Year Financial Results on February 29, 2016